Impact of a Specific Training Program on the Neuromodulation of Pain in Fibromyalgia Subjects

Fibromyalgia Clinical Trial

— DOUFISPORT  

Official title:

Impact of a Specific Training Program on the Neuromodulation of Pain in Fibromyalgia Subjects

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02486965
• Other study ID #: DOUFISPORT (RB 14.076)
• Status: Completed
• Phase: N/A
• Start date: October 7, 2015
• Est. completion date: October 21, 2021

Study information

• Verified date: April 2022
• Source: University Hospital, Brest
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Fibromyalgia affects 1.4 now 2.2% of the general population whose symptom is the presence of widespread pain in all four quadrants of the body. Currently, there is no causal treatment of fibromyalgia syndrome. The aim of this study is the evaluation of a specific training program on controls of pain in fibromyalgia patients by balancing the stress axis. The primary endpoint is the improvement in the Visual Analogue Scale VAS difference) measured during the test of the thermode (difference between the average VAS measured between the 10th and 40th second of P1 and the average VAS measured between the 10th and 40th of the second P3) between D0 (3rd consultation) and M24 (5th consultation - end of study visit), which will be compared in the two groups..Salivary cortisol is also tested.

Description:

A specific training program under the guidance of a physiotherapist, a professor of Adapted Physical Activity (APA) and individualized whose objective is to strengthen the parasympathetic tone and modulate the reactivity of the sympathetic system and the report of the Hypothalamic-Pituitary-Adrenal (HPA) axis.This training program consists of three sessions of 45 minutes of physical activity per week for 2 years. The exercise intensity is initially very low and will be gradually increased according to your abilities and your tolerance to stress. A 6-Minute Walk Test (6MWT) will be carried out by the physiotherapist and by Professor APA, every 6 months to monitor the progression. For tracking the training program, a phone call is scheduled every week during the first 3 months, then a phone call every 15 days during the following months until the end of the study.Evaluation of neuromodulation of pain will be measured thanks to thermodeTest , experimental method implementing a tonic thermal pain using a "Peltier type Thermode" 3 cm2 model TSA II and immersion in a bath of cold water. Participants will be randomly assigned to 2 groups, "Training" group or "Control" group. The control group is a training program supervised by physical therapists and teachers in Adapted Physical Activity, identical to the active program in its follow-up, but the intensity of the sessions is lower. Study schedule : - 1st visit : screening visit at D-30 - 2nd visit : inclusion at D-7 - 3rd visit at D0 - 4st visit between M6 and M9 - 5th visit at M24 The patients included in the study will receive in addition to the training program, taking into bio-psycho-social multidisciplinary.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 60
• Est. completion date: October 21, 2021
• Est. primary completion date: February 21, 2019
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

• Diagnosis of fibromyalgia is clearly established by the criteria of the American College of Rheumatology (ACR).
• Body Mass Index (BMI) between 18.5 and 24.9 kg / m² (normal weight at HAS).
• Spontaneous pain intensity greater than 3/10 on a VAS. Pain triggered by palpation must be equal to or greater than 4/10 of the EVA.
• Patients with a medical certificate to the sport.

Exclusion Criteria:

• Systemic disease, whether or not, generating pain musculoskeletal
• Heart disease, respiratory, endocrine, metabolic or neurological.
• Patients and patient pregnant lactating or planning to become pregnant within 2 years.
• Patients who have changed in the last 2 months any pharmacological treatment.
• Patients taking drugs that affect the heart rate variability
• Patients who have conditions that could affect the cortisol levels
• Patients with a psychiatric diagnosis of schizophrenia, delusional disorder and other personality disorders
• Patients taking substances affecting cortisol secretion

Related Conditions & MeSH terms

• Fibromyalgia
• Myofascial Pain Syndromes

Intervention

Device:
• thermode (TSA-II model)
thermal stimulation with test thermode

Other:
• Adapted Physical Activity

• Physical activity

Locations

Country	Name	City	State
France	CHRU Brest	Brest
France	CHU Rennes	Rennes

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Brest

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Pain as assessed by Visual analog scale		baseline to 24 months
Secondary	salivary cortisol	three times : 3th visit at Day 0, 4th visit between month 6 and 9, 5th visit at month 24	baseline to 24 months
Secondary	heart rate variability	three times : 2th visit at Day -7, 4th visit between month 6 and 9, 5th visit at month 24	baseline to 24 months
Secondary	Fibromyalgia Impact Questionnaire (FIQ)		baseline to 24 months
Secondary	Hospital Anxiety Depression Scale (HADS)		baseline to 24 months
Secondary	Pressure Pain Threshold (PSS)		baseline to 24 months
Secondary	International Physical Activity Questionnaire (IPAQ)		baseline to 24 months
Secondary	Pittsburgh Sleep Quality Index (PSQI)		baseline to 24 months
Secondary	Saint-Antoine Pain Questionnaire (SAPQ)		baseline to 24 months